Ashley M Kroon Van Diest1,2, Scott W Powers3,4,5. 1. Department of Pediatric Psychology and Neuropsychology, Nationwide Children's Hospital, Columbus, OH, USA. 2. Department of Pediatrics, The Ohio State University, Columbus, OH, USA. 3. Division of Behavioral Medicine and Clinical Psychology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA. 4. Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA. 5. Headache Center, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA.
Abstract
PURPOSE OF REVIEW: To highlight current evidence supporting the prescription of cognitive behavioral therapy (CBT) as part of first-line preventive treatment for children and adolescents with headache and discuss a research strategy aimed at: (1) understanding how and why CBT works, and (2) developing effective and efficient approaches for integrating CBT into headache specialty, neurology, and primary care settings. RECENT FINDINGS: Although preventive medications for pediatric headache and migraine are commonly prescribed, recent meta-analyses and an NIH-funded, multi-center clinical trial suggests that the effect of pill-taking therapies may be mostly due to a placebo effect. These findings have led to greater consideration of prescription of non-pharmacological therapies as first-line interventions (either alone or in combination with pill-based therapy). A literature that extends back to the 1980s and includes recent clinical trials and meta-analyses demonstrates that CBT decreases headache frequency and related disability in youth with headache and migraine and has a favorable benefit to risk profile with almost no negative side effects. SUMMARY: CBT has been repeatedly demonstrated as effective in treating pediatric headache and migraine. As such, it should be considered as part of first-line preventive treatment for pediatric headache (either alone or in combination with a pill-based therapy). We need to better understand how this therapy works and what makes it distinct (if anything) from the placebo effect. What we need to achieve is empirical support for efficient access to this evidence-based treatment and clarity on how to match the intensity of non-pharmacological intervention to the needs of our patients at the time they present for care.
PURPOSE OF REVIEW: To highlight current evidence supporting the prescription of cognitive behavioral therapy (CBT) as part of first-line preventive treatment for children and adolescents with headache and discuss a research strategy aimed at: (1) understanding how and why CBT works, and (2) developing effective and efficient approaches for integrating CBT into headache specialty, neurology, and primary care settings. RECENT FINDINGS: Although preventive medications for pediatric headache and migraine are commonly prescribed, recent meta-analyses and an NIH-funded, multi-center clinical trial suggests that the effect of pill-taking therapies may be mostly due to a placebo effect. These findings have led to greater consideration of prescription of non-pharmacological therapies as first-line interventions (either alone or in combination with pill-based therapy). A literature that extends back to the 1980s and includes recent clinical trials and meta-analyses demonstrates that CBT decreases headache frequency and related disability in youth with headache and migraine and has a favorable benefit to risk profile with almost no negative side effects. SUMMARY: CBT has been repeatedly demonstrated as effective in treating pediatric headache and migraine. As such, it should be considered as part of first-line preventive treatment for pediatric headache (either alone or in combination with a pill-based therapy). We need to better understand how this therapy works and what makes it distinct (if anything) from the placebo effect. What we need to achieve is empirical support for efficient access to this evidence-based treatment and clarity on how to match the intensity of non-pharmacological intervention to the needs of our patients at the time they present for care.
Authors: Rachelle R Ramsey; Jamie L Ryan; Andrew D Hershey; Scott W Powers; Brandon S Aylward; Kevin A Hommel Journal: Headache Date: 2014-04-17 Impact factor: 5.887
Authors: Scott W Powers; Susmita M Kashikar-Zuck; Janelle R Allen; Susan L LeCates; Shalonda K Slater; Marium Zafar; Marielle A Kabbouche; Hope L O'Brien; Chad E Shenk; Joseph R Rausch; Andrew D Hershey Journal: JAMA Date: 2013-12-25 Impact factor: 56.272
Authors: John W Kroner; Andrew D Hershey; Susmita M Kashikar-Zuck; Susan L LeCates; Janelle R Allen; Shalonda K Slater; Marium Zafar; Marielle A Kabbouche; Hope L O'Brien; Chad E Shenk; Joseph R Rausch; Ashley M Kroon Van Diest; Scott W Powers Journal: Headache Date: 2016-03-18 Impact factor: 5.887
Authors: Dawn C Buse; Aubrey N Manack; Kristina M Fanning; Daniel Serrano; Michael L Reed; Catherine C Turkel; Richard B Lipton Journal: Headache Date: 2012-07-25 Impact factor: 5.887
Authors: Rachelle R Ramsey; Christina E Holbein; Scott W Powers; Andrew D Hershey; Marielle A Kabbouche; Hope L O'Brien; Joanne Kacperski; Jeffrey Shepard; Kevin A Hommel Journal: Cephalalgia Date: 2018-04-10 Impact factor: 6.292
Authors: Hadas Nahman-Averbuch; Victor J Schneider; Leigh Ann Chamberlin; Ashley M Kroon Van Diest; James L Peugh; Gregory R Lee; Rupa Radhakrishnan; Andrew D Hershey; Scott W Powers; Robert C Coghill; Christopher D King Journal: Pain Date: 2021-02-01 Impact factor: 7.926